Erika Lisabeth , PhD
Education
BS, Chemistry, Michigan State University, 1999
Post-doctoral Training, Cancer Biology, Sanford Burnham Prebys Medical Discovery Institute, 2009
PhD, Chemistry and Biochemistry , University of California, San Diego, 2003
Employment
Assistant Professor, Michigan State University, East Lansing, 2014 - Present
Publications
Reversion of a RND transporter pseudogene uncovers latent stress resistance in Brucella ovis (2025)
AI is a viable alternative to high throughput screening: a 318-target study. Scientific reports (2024)
Development of a Cell-Based AlphaLISA Assay for High-Throughput Screening for Small Molecule Proteasome Modulators. ACS omega (2023)
Development of a 5-HT7 receptor antibody for the rat: the good, the bad, and the ugly. Naunyn-Schmiedeberg's archives of pharmacology (2023)
Mass Spectrometry, Structural Analysis, and Anti-Inflammatory Properties of Photo-Cross-Linked Human Albumin Hydrogels ACS Applied Bio Materials (2022)
Transforming growth factor β1 increases expression of contractile genes in human pulmonary arterial smooth muscle cells by potentiating sphingosine-1-phosphate signaling Molecular Pharmacology (2021)
Rho-mediated signaling promotes BRAF inhibitor resistance in de-differentiated melanoma cells Oncogene (2020)
5-Aryl-1,3,4-oxadiazol-2-ylthioalkanoic Acids: A Highly Potent New Class of Inhibitors of Rho/Myocardin-Related Transcription Factor (MRTF)/Serum Response Factor (SRF)-Mediated Gene Transcription as Potential Antifibrotic Agents for Scleroderma Journal of Medicinal Chemistry (2019)
Identification of Pirin as a Molecular Target of the CCG-1423/CCG-203971 Series of Antifibrotic and Antimetastatic Compounds ACS Pharmacology and Translational Science (2019)
The Rho/MRTF pathway inhibitor CCG-222740 reduces stellate cell activation and modulates immune cell populations in Kras G12D ; Pdx1-Cre (KC) mice Scientific Reports (2019)
